Abstract
The administration of milrinone through inhalation has been studied in only a few animal and human studies. Compared to the intravenous administration, inhaled milrinone has been shown to reduce pulmonary artery pressure without systemic hypotension. Therefore, this approach could represent an alternative to nitric oxide. This current state of knowledge of intravenous and inhaled milrinone is presented and summarized.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Administration, Inhalation
-
Animals
-
Endpoint Determination / methods
-
Heart Function Tests
-
Humans
-
Hypertension, Pulmonary / drug therapy*
-
Hypertension, Pulmonary / etiology
-
Hypertension, Pulmonary / physiopathology
-
Injections, Intravenous
-
Milrinone / administration & dosage*
-
Milrinone / pharmacology
-
Monitoring, Physiologic
-
Phosphodiesterase Inhibitors / administration & dosage*
-
Phosphodiesterase Inhibitors / pharmacology
-
Swine
-
Thoracic Surgical Procedures* / adverse effects
-
Treatment Outcome
Substances
-
Phosphodiesterase Inhibitors
-
Milrinone